Enpatoran in COVID‐19 pneumonia: Safety and efficacy results from a phase II randomized trial
Abstract Enpatoran is a selective inhibitor of toll‐like receptors 7 and 8 (TLR7/8) that potentially targets pro‐inflammatory pathways induced by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). A phase II study conducted in Brazil, the Philippines, and the USA during the early pandemic...
Saved in:
Main Authors: | John E. McKinnon (Author), Joel Santiaguel (Author), Claudia Murta de Oliveira (Author), Dongzi Yu (Author), Mukhy Khursheed (Author), Flavie Moreau (Author), Lena Klopp‐Schulze (Author), Jamie Shaw (Author), Sanjeev Roy (Author), Amy H. Kao (Author), the ANEMONE Study Team (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8
by: Andreas Port, et al.
Published: (2021) -
Household size: an overlooked confounder when considering inequalities in food choice
by: Loretta McKinnon
Published: (2014) -
A Mother's Year Book
by: McSwain, Mary McKinnon [Editor]; Morton, Francis McKinnon [Editor] -
Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus
by: Kosalaram Goteti, et al.
Published: (2024) -
The Role of Multi-data Evaluations in the Site-based Management: An Examination of an Innovative Teacher Professional Growth Plan
by: Tim Goddard, et al.
Published: (2006)